Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: thapsigargin analogues - Rebus Holdings

Next Previous
Search
Drug Profile

Research programme: thapsigargin analogues - Rebus Holdings

Alternative Names: Ac-GKAFRR-L12ADT; G-114; G-115; G-301; Plant-derived cytotoxin- Rebus Holdings; Thapsigargin analogues research programme- Rebus Holdings

Latest Information Update: 26 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenSpera
  • Developer Rebus Holdings
  • Class Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV)
  • 01 Aug 2016 GenSpera is now called Inspyr Therapeutics
  • 06 May 2015 GenSpera has patents pending for injectable cancer compositions of thapsigargin-containing prodrugs in 17 countries, including Europe, Eurasia, Japan, China, Brazil and USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top